Drug Profile
S-nitrosoglutathione inhalation - Alpine Immune Sciences
Alternative Names: GSNO; N 30-201; S-nitroso-GSH; S-nitroso-L-glutathioneLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator NitroMed
- Developer Nivalis Therapeutics
- Class Antiplatelets; Bronchodilators; Oligopeptides; S-nitrosothiols; Small molecules
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
Most Recent Events
- 25 Jul 2017 Alpine Immune Sciences has merged with Nivalis Therapeutics forming Alpine Immune Sciences
- 01 Jul 2010 No development reported - Phase-I for Asthma in USA (Inhalation)
- 01 Jul 2010 No development reported - Phase-I for Chronic obstructive pulmonary disease in USA (Inhalation)